Keyphrases
Myasthenia Gravis
100%
Systematic Literature Review
100%
Single-center Experience
100%
Immune Checkpoint Inhibitors
100%
Life-threatening
22%
Adverse Events
22%
Intravenous Immunoglobulin (IVIg)
22%
Clinical Features
11%
Respiratory Failure
11%
New Disease
11%
Symptom Severity
11%
Metastatic Melanoma
11%
Large Cohort
11%
Early Use
11%
Fatal Complication
11%
Diagnostic Performance
11%
Plasmapheresis
11%
Myositis
11%
Acute Onset
11%
Initial Symptom
11%
Rapid Progression
11%
Diagnostic Features
11%
Absence of Evidence
11%
New Onset
11%
Diagnostic Management
11%
Prospective Longitudinal Study
11%
Current Recommendations
11%
Management Approach
11%
First-line Therapy
11%
Institutional Database
11%
Feature Management
11%
Anti-PD-1
11%
Disease Flare
11%
Medicine and Dentistry
Systematic Review
100%
Myasthenia gravis
100%
Immune Checkpoint Inhibitor
100%
Adverse Event
22%
Immunoglobulin
22%
Malignant Neoplasm
11%
Respiratory Failure
11%
Disease Exacerbation
11%
Metastatic Melanoma
11%
Plasmapheresis
11%
Myositis
11%
Pharmacology, Toxicology and Pharmaceutical Science
Myasthenia gravis
100%
Immune Checkpoint Inhibitor
100%
Adverse Event
22%
Immunoglobulin
22%
Malignant Neoplasm
11%
Disease Exacerbation
11%
Respiratory Failure
11%
Metastatic Melanoma
11%
Myositis
11%
Immunology and Microbiology
Myasthenia gravis
100%
Immune Checkpoint Inhibitor
100%
Intravenous Immunoglobulin
22%
Plasmapheresis
11%
Myositis
11%
Neuroscience
Myasthenia gravis
100%
Systematic Review
100%
Intravenous Immunoglobulin
22%
Myositis
11%
Longitudinal Study
11%